Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorUrdiciain-Ezpeleta, A. (Alejandro)-
dc.creatorMeléndez, B. (Bárbara)-
dc.creatorRey, J.A. (Jorge Alberto)-
dc.creatorIdoate, M.A. (Miguel Ángel)-
dc.creatorSaez-Castresana, J. (Javier)-
dc.date.accessioned2023-04-18T06:49:32Z-
dc.date.available2023-04-18T06:49:32Z-
dc.date.issued2018-
dc.identifier.citationUrdiciain-Ezpeleta, A. (Alejandro); Meléndez, B. (Bárbara); Rey, J.A. (Jorge Alberto); et al. "Panobinostat potentiates temozolomide effects and reverses epithelial-mesenchymal transition in glioblastoma cells". Epigenomes. 2 (1), 2018,es_ES
dc.identifier.issn2075-4655-
dc.identifier.urihttps://hdl.handle.net/10171/65958-
dc.description.abstractGlioblastoma is the most common form of glioma, as well as the most aggressive. Patients suffering from this disease have a very poor prognosis. Surgery, radiotherapy, and temozolomide are the only approved treatments nowadays. Panobinostat is a pan-inhibitor of histone deacetylases (HDACs) that has been shown to break some pathways which play an important role in cancer development. A global intention of using panobinostat as a therapeutic agent against glioblastoma is beginning to be a reality. We have treated the LN405 glioblastoma cell line with temozolomide, panobinostat, and combined treatment, in order to test apoptosis, colony formation, and a possible molecular reversion of the mesenchymal phenotype of the cells to an epithelial one. Our results show that panobinostat decreased N-cadherin levels in the LN405 glioblastoma cell line while it increased the expression of E-cadherin, which might be associated with a mesenchymal–epithelial transition in glioblastoma cells. Colony formation was reduced, and apoptosis was increased with treatments. Our research highlights the importance of panobinostat as a potential adjuvant therapy to be used with temozolomide to treat glioblastoma and the advantages of the combined treatment versus temozolomide alone, which is currently the first-line treatment used to treat this tumores_ES
dc.description.sponsorshipFinancial support for this work was provided by a grant from the Fundación Universidad de Navarra, Pamplona, Spain. A.U. received a predoctoral fellowship from the Asociación de Amigos de la Universidad de Navarra, Pamplona, Spaines_ES
dc.language.isoenges_ES
dc.publisherMDPI AGes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectPanobinostates_ES
dc.subjectTemozolomidees_ES
dc.subjectGlioblastomaes_ES
dc.subjectEpithelial-mesenchymal transitiones_ES
dc.titlePanobinostat potentiates temozolomide effects and reverses epithelial-mesenchymal transition in glioblastoma cellses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.identifier.doi10.3390/epigenomes2010005-
dadun.citation.number1es_ES
dadun.citation.publicationNameEpigenomeses_ES
dadun.citation.volume2es_ES

Ficheros en este ítem:
Vista previa
Fichero
epigenomes-02-00005-v2.pdf
Descripción
Tamaño
1.61 MB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.